Mitochondria-targeting peptide

SS-31 (Elamipretide)

SS-31 is another name for elamipretide, which FDA gave accelerated approval in 2025 for Barth syndrome; its half-life is about 3 hours in the app and about 3 to 4 hours in FDA's review.1,2,3

Emerging evidenceGet the app

Level after one dose

SS-31 (Elamipretide) after one dose: 50% at ~3 h, 25% at 6 h, 12.5% at 9 h.

Drawn from the half-life in the app's model, ~3 h. The model's figures

1

How Milligram users log it

Track your protocol with Milligram.

3%The 19th most tracked compound in Milligram: of people who track compounds in Milligram logged SS-31 (Elamipretide) in the last 90 days.

Schedule

  1. Daily72%
  2. Every other day21%
  3. Twice a week5%
  4. Weekly0%
  5. Less often1%
Among people with three or more logged doses, by the average gap between their doses.

Logged doses

Half of people logged between 1 and 3.4 mg per dose; the median was 2 mg.

Each person's usual logged amount. The bar starts at zero; the shaded part is the middle half, the mark the median.

Tracked alongside

The share of people logging SS-31 (Elamipretide) who also logged each.

From dose logs in the Milligram app, 90 days to 15 November 2026. Aggregated and anonymous. This describes what people recorded, not what anyone should take.

SS-31 is another name for elamipretide, a peptide that FDA's label for Forzinity calls a "mitochondrial cardiolipin binder".1,4 FDA approved Forzinity injection under accelerated approval, with the indication "to improve muscle strength in adult and pediatric patients with Barth syndrome weighing at least 30 kg".4,5 The label states that it rests on "an improvement in knee extensor muscle strength, an intermediate clinical endpoint" and that continued approval "may be contingent upon verification and description of clinical benefit in a confirmatory trial".4

Elamipretide has also been given to people in trials in primary mitochondrial myopathy, heart failure, myocardial infarction, Leber hereditary optic neuropathy and age-related macular degeneration.6,7,19,21,8

The label states that elamipretide "localizes to the inner mitochondrial membrane and improves mitochondrial morphology and function".4 Thompson and colleagues write that SS-31 "binds to cardiolipin via electrostatic and hydrophobic interactions" and "is hypothesized to sustain the cristae network and remediate bioenergetic dysfunction".1 A 2025 review by Sabbah and colleagues states: "Despite initial descriptions of elamipretide's MOA involving reactive oxygen species scavenging, the last ten years have provided a significant expansion of how this peptide influences mitochondrial bioenergetics".9 The review's disclosures list research support from Stealth BioTherapeutics for one author and, for two others, funding from 2 AHA awards that "utilize elamipretide".9

FDA's review describes Barth syndrome as "a rare, infantile-onset, X-linked recessive, mitochondrial disease" and as "caused by defects in the TAFAZZIN gene, which result in cardiolipin abnormalities that lead to mitochondrial dysfunction".3 In the resubmission review, the reviewers who recommended a Complete Response noted that "elamipretide does not directly target the underlying genetic defect that causes BTHS, nor does it meaningfully impact the elevated cardiolipin ratio, the direct sequelae of the mutation in the Tafazzin gene".3

4

Half-life and pharmacokinetics

Values from the Milligram app's model.

Half-life
~3 h
Bioavailability
85%
Typical dose
20–60 mg/day
Route
SubQ
Time to peak
~1.5 h

FDA's review lists a half-life of "~3 - 4 hours", and the label's pharmacokinetics section gives no half-life figure.3

Table 4.1Half-life and pharmacokinetics4 rows
ParameterApp's figureReported in the sources
Half-lifeAbout 3 hoursFDA's review lists "~3 - 4 hours"; after a single 40 mg subcutaneous dose the mean was 3.16 hours (SD 0.53) in 32 healthy volunteers and 1.48 hours (SD 0.29) in 7 people with Barth syndrome, and 2.8 hours (SD 0.3) at steady state after 40 mg once daily for 7 days (n=5)3
BioavailabilityAbout 85% by subcutaneous injectionThe label states: "The absolute bioavailability following subcutaneous administration is approximately 92%"4
Time to peakAbout 1.5 hoursThe label states that maximum concentrations "were reached between 0.5 to 1 hour after subcutaneous administration"; FDA's review gives a mean of 0.63 hours (SD 0.16) in healthy volunteers and 0.60 (SD 0.19) in people with Barth syndrome4,3
EliminationDuration of activity about 24 hoursThe label states that elamipretide and its metabolites M1 and M2 are excreted in the urine and that at 48 hours "approximately 100% of the FORZINITY dose was recovered in the urine" in patients with normal renal function4. The sources cited give no duration of activity.

The label states that exposure "increases proportionally over a dose range of 2 to 80 mg following daily subcutaneous injections with minimal accumulation".4

The chart is a model drawn from the app's half-life and time to peak, not measured concentrations, with the once-daily interval stated on the label; the label and FDA figures above differ.4

Level over 3 days

Interval between doses

Level, as a share of the peak after one 40 mg dose

As studied: every day4. As logged in Milligram: the share of people with three or more logged doses on each schedule (How Milligram users log it).

An illustration from a pharmacokinetic model using a half-life of 3 hours. It is not a measured level or a suggested dose.

5

What the Forzinity vial label states per mL

The label gives the strength as "280 mg/3.5 mL (80 mg/mL)" in single-patient-use vials.4

Strength converter

US label strength: 80 mg per mL4

Arithmetic only: the amount is the volume times the strength. The vial's own label states its strength.

6

Human studies

A query of ClinicalTrials.gov on 16 November 2026 for elamipretide as an intervention returned 23 records, and the table gives the studies with efficacy results reported in the sources cited.

Table 6.1Human studies10 rows
Study and yearDesignPeopleDose and lengthMain result
Thompson and colleagues, 2021 (TAZPOWER, randomized part)1Randomized, double-blind, placebo-controlled crossover trial at one site12 males with genetically confirmed Barth syndrome, mean age 19.5 years40 mg subcutaneously once daily for 12 weeks or placebo for 12 weeks, 4-week washout betweenNeither primary endpoint was met: 6-minute walk difference from placebo -0.8 m (p = 0.97) and total fatigue score +0.06 (p = 0.89)
Thompson and colleagues, 2021 (TAZPOWER, open-label part)Open-label, single arm, no placebo group10 people entered; 8 reached week 36; two stopped because of injection site reactions40 mg subcutaneously once daily, 36 weeksCompared with baseline, 6-minute walk +95.9 m (p = 0.02), total fatigue -2.1 points (p = 0.03) and knee extensor strength +56.0 newtons (p = 0.001) in the 8 who reached week 36
Thompson and colleagues, 2024 (TAZPOWER extension)10Open-label extension to 168 weeks10 people entered; 8 reached week 16840 mg subcutaneously once daily6-minute walk improved from extension baseline at all time points (cumulative 96.1 m at week 168, P = .003)
Karaa and colleagues, 2023 (MMPOWER-3)6Randomized, double-blind, placebo-controlled phase 3218 people with genetically confirmed primary mitochondrial myopathy (109 per group)40 mg subcutaneously once daily, 24 weeksPrimary endpoints not met: 6-minute walk difference -3.2 m (95% CI -18.7 to 12.3; p = 0.69); total fatigue difference -0.07 (95% CI -0.69 to 0.54; p = 0.81)
Karaa and colleagues, 2018 (MMPOWER)11Phase 1/2, multicentre, randomized, double-blind, placebo-controlled, dose escalation36 people with genetically confirmed primary mitochondrial myopathyIntravenous 0.01, 0.1 and 0.25 mg/kg/h, or placebo, over 2 hours daily for 5 consecutive days (one cohort per dose); primary measure after 5 daysHighest dose group walked a mean of 64.5 m farther at day 5 against a change of 20.4 m with placebo (p = 0.053) and a dose-dependent increase in distance walked (p = 0.014), with no difference between the highest dose and placebo 2 days after stopping (61.7 vs 38.5 m; p = 0.387); no significant differences in other efficacy and safety endpoints
Ehlers and colleagues, 2025 (ReCLAIM-2)8Randomized, placebo-controlled, double-masked, multicentre phase 2176 people aged 55 or older with dry age-related macular degeneration and noncentral geographic atrophy (the protocol was amended to limit inclusion to noncentral atrophy)40 mg subcutaneously once daily, 48 weeksNeither primary endpoint reached significance; additional predefined endpoints, with nominal P values, were a 43% lower mean progression of total ellipsoid zone loss (P = 0.0034) and 47% for partial loss (P = 0.0040) versus placebo at week 48, and a gain of 10 or more letters in low-luminance visual acuity in 14.6% versus 2.1% (P = 0.0404)
Butler and colleagues, 2020 (PROGRESS-HF)7Randomized, double-blind, placebo-controlled phase 271 people with heart failure with reduced ejection fraction (LVEF 40% or less)Placebo, 4 mg or 40 mg subcutaneously once daily for 28 consecutive daysChange in left ventricular end systolic volume from baseline to week 4 was not significantly different from placebo (4 mg: P = 0.90; 40 mg: P = 0.28)
Gibson and colleagues, 2016 (EMBRACE STEMI)19Multicentre, randomized, double-blind phase 2a trial of MTP-131 versus placeboPeople with first-time anterior ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention for a proximal or mid left anterior descending artery occlusionIntravenous 0.05 mg/kg/h for 1 hour, or placeboPrimary endpoint not met: infarct size by CK-MB area under the curve over 72 hours was 5785 ± 426 ng h/mL on placebo and 5570 ± 486 on MTP-131 (P = NS); no improvement in pre-specified magnetic resonance imaging, angiographic, electrocardiographic or clinical outcomes
Daubert and colleagues, 201720Double-blind, placebo-controlled, ascending-dose trialPeople with heart failure with reduced ejection fraction (35% or less): 8 in each elamipretide cohort and 12 on placeboA single 4-hour infusion of 0.005, 0.05 or 0.25 mg/kg/h, or placeboCompared with placebo, left ventricular end-diastolic volume was 18 mL lower (P = 0.009) and end-systolic volume 14 mL lower (P = 0.005) at the end of infusion in the highest dose cohort; no serious adverse events
Karanjia and Sadun, 202421Phase 2, prospective, randomized, vehicle-controlled, single-centre trial12 people aged 18 to 50 with genetically confirmed m.11778G>A Leber hereditary optic neuropathyElamipretide 1% topical ophthalmic solution for 52 weeks double-masked, then open-label for up to 108 more weeksThe change from baseline in best-corrected visual acuity in treated eyes was not significantly different from vehicle eyes at any time point; no serious adverse events were reported

Stealth BioTherapeutics funded the TAZPOWER, MMPOWER, MMPOWER-3 and ReCLAIM-2 trials, as each paper states, and ClinicalTrials.gov lists it as lead sponsor of PROGRESS-HF.1,11,6,8,12 In the 168-week extension paper, three authors are Stealth employees and two report research support from the company; in ReCLAIM-2 two authors are listed as Stealth employees, several others list consulting for, research support from or grants from Stealth, and the funder "participated in the study design and conduction, data analysis and interpretation, and preparation of the manuscript".10,8

Deeper analysis: TAZPOWER and the basis for FDA's accelerated approval

Thompson, Hornby and colleagues reported TAZPOWER in Genetics in Medicine in 2021: at Johns Hopkins Hospital, 12 males with genetically confirmed Barth syndrome received 40 mg of elamipretide or placebo for 12 weeks each, with a 4-week washout, and the primary endpoints were the 6-minute walk distance and the total fatigue score on the Barth Syndrome Symptom Assessment.1 The paper states that Stealth BioTherapeutics "designed the trial in conjunction with the Johns Hopkins University study team", that the sponsor "was not involved with data collection" but "was involved with data analysis and the preparation of this publication", and that one author is employed by the company while "The other authors declare no conflicts of interest".1

Part 1 found no significant difference from placebo on either primary endpoint or on any other secondary endpoint, including knee extensor strength (+6.7 newtons; p = 0.65).1 In the extension the authors write: "The significant increases in primary and secondary endpoints were observed in the open-label extension part of the study and lacked a placebo-controlled group. Thus, placebo effect cannot be ruled out as a factor in the BTHS symptom improvement".1 In part 1, 12 of 12 people on elamipretide and 10 of 12 on placebo had at least one treatment-emergent adverse event, and the paper reports one serious event, a hospitalization for costochondritis, judged unrelated to elamipretide.1

FDA's integrated review states that part 1 "did not show superiority of elamipretide to placebo at the end of 12 weeks of treatment" on the primary endpoints (p=0.97 and p=0.89) and that "none of the secondary endpoints achieved even nominal statistical significance (p=0.21-1.00)".3 In the first review cycle its reviewers wrote that "our predominant concerns were related to bias involving these endpoints in this single-arm, open-label study that were effort-dependent and/or could be impacted by subjects knowing they were receiving elamipretide".3 On resubmission the clinical and biostatistical reviewers and the Cross-Discipline Team Leader recommended a Complete Response again, citing "the open-label design of SPIBA-201, Part 2, the lack of a control arm, and the potential impact of known and unknown sources of bias (e.g., subject attrition, effort-dependence)".3 The signatory authority "agrees that there is more uncertainty than we would accept for more common diseases" but accepted it for a disease with about 150 people in the United States and no approved treatments, pointing to a "negligible HHD response with placebo" in part 1 and a handheld dynamometry increase that was "consistently maintained over more than 3 years of follow-up".3 The natural history comparison (8 treated and 19 untreated people; 6-minute walk difference 79.7 m at week 64, P = 0.0004) lists as limitations "its observational nature and the limited number of patients available", states that the trial was funded by Stealth, and lists two Stealth employees among its authors; FDA's first-cycle review states that "the externally controlled design could not overcome the major concerns identified for SPIBA-201, Part 2 regarding bias from knowledge of treatment assignment".13,3 The approval letter requires "a randomized, double-blind, placebo-controlled trial in patients 5 years and older with Barth syndrome to verify and describe the clinical benefit", and ClinicalTrials.gov lists the 4TAZPower trial as a 72-week, randomized, placebo-controlled trial sponsored by Stealth BioTherapeutics.5,14

Deeper analysis: MMPOWER-3

Karaa, Bertini, Carelli and colleagues reported MMPOWER-3 in Neurology in 2023: 218 people with genetically confirmed primary mitochondrial myopathy were randomized 1:1 to 40 mg a day of subcutaneous elamipretide or placebo for 24 weeks, with 6-minute walk distance and total fatigue on the Primary Mitochondrial Myopathy Symptom Assessment as primary endpoints.6 The authors write: "Overall, participants who received elamipretide did not meet either primary or secondary endpoints".6 A post hoc analysis by genetic class found a 25.2 m difference favoring elamipretide in the 58 people with nuclear DNA alterations (95% CI 3.1 to 47.3; p = 0.03) and a difference of -11.0 m favoring placebo in the 153 with mitochondrial DNA alterations (95% CI -28.1 to 6.1; p = 0.21).6 The authors write that "the phase 3 population was only moderately impaired based on the average PMMSA fatigue score" and that these findings "warrant further investigation".6

Adverse events were reported by 107 of 109 (98.2%) on elamipretide and 83 of 109 (76.1%) on placebo, serious adverse events by 5 of 109 (4.6%) and 3 of 109 (2.8%) and "not deemed to be treatment related", and adverse events leading to discontinuation by 8 of 109 (7.3%) and 2 of 109 (1.8%).6 The authors write that "Most of the AEs were mild or moderate in intensity" and that no participant had an adverse event with an outcome of death or hospitalization, while FDA's review, which labels the trial SPIMM-301 (registered as NCT03323749), gives discontinuations for adverse events as 7% versus 3%, and ClinicalTrials.gov lists NCT03323749 as terminated, with the reason "Part1,double blind portion of the trial did not meet the primary end points".6,3,15 The paper states that the trial "was funded by Stealth BioTherapeutics", that D. A. Brown "is an employee of Stealth BioTherapeutics", and thanks two Stealth staff "for their support of the clinical study endpoints, statistical analysis, and interpretation of the study results"; the first author reports research grant, travel and consulting payments from Stealth, and the paper lists J. Finman and James Schiffer as consultants for Stealth BioTherapeutics.6

7

Doses reported in studies and on the label

The app lists a typical dose of 20 to 60 mg a day. The label gives 40 mg once daily, and 20 mg once daily with eGFR under 30 mL/minute not on dialysis; a 60 mg once-daily subcutaneous dose for 48 weeks appears in the registry record and in FDA's review of the nuclear DNA phase 3 trial, and FDA's review lists 60 mg every 3 hours for five doses in healthy volunteers.4

Table 7.1Doses reported in studies and on the label5 rows
SourceDoseFrequencyLength
Forzinity label, patients with Barth syndrome weighing at least 30 kg440 mg subcutaneouslyOnce dailyNo length stated
Forzinity label, adults with eGFR under 30 mL/minute and not on dialysis420 mg subcutaneouslyOnce dailyNo length stated
TAZPOWER, MMPOWER-3, ReCLAIM-21,6,840 mg subcutaneouslyOnce daily12 weeks (TAZPOWER), 24 weeks (MMPOWER-3), 48 weeks (ReCLAIM-2)
PROGRESS-HF74 mg or 40 mg subcutaneouslyOnce daily28 days
SPIMD-301 (NCT05162768), registry record and FDA review18,360 mg subcutaneouslyOnce daily48 weeks

The label states that adverse reactions occurring more commonly on elamipretide than on placebo "include injection site reactions such as injection site erythema, pain, induration, pruritus, bruising, and urticaria".4 In its table for the randomized Barth syndrome trial, any local administration reaction occurred in 12 of 12 (100%) on elamipretide and 8 of 12 (67%) on placebo.4 The label reports hypersensitivity reactions "including serious allergic reactions requiring emergency medical intervention", which "may occur within minutes to months after treatment initiation", and lists serious hypersensitivity to elamipretide or any excipient as a contraindication.4 It reports that increases in absolute eosinophil counts were noted frequently in studies of 30 days or longer, peaked around 90 days and returned to baseline after 6 to 12 months of continuous exposure or after discontinuation, and that the elevation "was not associated with clinical manifestations or changes in other laboratory parameters". It states that Forzinity "is not approved for use in neonates", reports fatal reactions to benzyl alcohol in low-birth weight and preterm neonates who received benzyl alcohol-containing drugs intravenously, and states that Forzinity contains 20 mg of benzyl alcohol per mL.4

In ReCLAIM-2, 34 of 117 (29%) on elamipretide and 8 of 59 (14%) on placebo discontinued the study early, and FDA's review reports serious adverse events in 18 of 117 (15.4%) on elamipretide and 6 of 59 (10.2%) on placebo, adverse events leading to discontinuation in 23% versus 14%, and two deaths in the elamipretide group (one from coronavirus infection, one from acute respiratory failure) that it calls "unlikely to be related to elamipretide".3,8 It also reports 20 deaths among 171 participants in the expanded access programme, none "deemed to be related to elamipretide in the opinion of the treating physicians", and calls the utility of this descriptive data limited.3 In PROGRESS-HF, "Rates of any study drug-related adverse events were similar in the 3 groups", and in MMPOWER the most common adverse event was headache (6 people, 16.7%) with no deaths, serious adverse events or discontinuations reported.7,11 In the nuclear DNA phase 3 trial (SPIMD-301, 60 mg a day versus placebo, 51 people in each group for 48 weeks), FDA's review reports injection site erythema in 51% versus 8% and pruritus in 45% versus 12%, serious adverse events in 7 people versus 1, and one death in the elamipretide group, a cardiac arrest at about 24 weeks that the investigator and sponsor assessed as unrelated to elamipretide; FDA wrote that "the available evidence and clinical context suggest the death was related to subject’s underlying medical conditions rather than elamipretide", with no autopsy performed.3

The app lists cardiac MRI, VO2 max and lactate as markers. In PROGRESS-HF the primary measure was left ventricular end systolic volume assessed by cardiac magnetic resonance imaging, and the change from baseline to week 4 "was not significantly different" from placebo at either dose.7 The TAZPOWER paper reports no statistically significant change in the monolysocardiolipin to cardiolipin ratio in part 1 or part 2, while the 168-week paper states that "MLCL/CL values showed improvement, correlating to important clinical outcomes".1,10

FDA's approval letter for NDA 215244 carries an electronic signature dated 19 September 2025 and states that the application "is approved under accelerated approval".5 The label states that "The safety and effectiveness of FORZINITY have not been established in pediatric patients weighing less than 30 kg" and that clinical studies "did not enroll subjects with Barth syndrome aged 65 years and older".4

The World Anti-Doping Agency's 2026 Prohibited List text does not name SS-31 or elamipretide: a text search of the list on 16 November 2026 for "elamipretide", "SS-31", "SS31", "MTP-131" and "Bendavia" returned no match.16 Its section S0 prohibits at all times "Any pharmacological substance which is not addressed by any of the subsequent sections of the List and with no current approval by any governmental regulatory health authority for human therapeutic use", and the list text does not state how S0 applies to elamipretide after the FDA approval.16

11

Storage and handling

The label states "Store refrigerated at 2°C to 8°C (36°F to 46°F). Do not freeze", and that after the first dose the vial in use "can be stored either refrigerated 2°C to 8°C (36°F to 46°F) or at room temperature between 20°C to 25°C (68°F to 77°F)", and "Discard vials 8 days after first opening".4

The confirmatory trial the approval letter requires has not reported: ClinicalTrials.gov lists 4TAZPower as recruiting, with an estimated primary completion date of 30 September 2029.14 The phase 3 ReNEW trial in dry age-related macular degeneration (313 people) is listed as active, not recruiting, with an estimated primary completion in August 2027 and no results posted.17 The phase 3 trial in primary mitochondrial disease from nuclear DNA mutations (NCT05162768) is listed as completed with no results posted on ClinicalTrials.gov; FDA's review gives its safety results but the sources cited give no efficacy results, and the nuclear DNA subgroup finding of MMPOWER-3 was derived post hoc.18,6 Limitation statements for the 168-week extension paper and PROGRESS-HF are not given because only their PubMed records were available.

What is SS-31?

SS-31 is another name for elamipretide, which FDA approved as Forzinity under accelerated approval for Barth syndrome in patients weighing at least 30 kg.1,4

What is the half-life of SS-31?

The app lists a half-life of about 3 hours, and FDA's review lists "~3 - 4 hours".3

Is SS-31 approved by the FDA?

Yes, as elamipretide: FDA approved Forzinity under accelerated approval on 19 September 2025 for Barth syndrome in patients weighing at least 30 kg, and the label states that continued approval "may be contingent upon verification and description of clinical benefit in a confirmatory trial".5,4

What is the bioavailability of SS-31?

The app lists 85% for subcutaneous injection, and the Forzinity label states an absolute bioavailability of approximately 92% following subcutaneous administration.4

How long does SS-31 take to reach its peak level?

The app lists about 1.5 hours, and the label states that maximum concentrations "were reached between 0.5 to 1 hour after subcutaneous administration".4

Did MMPOWER-3, a phase 3 trial of SS-31 in primary mitochondrial myopathy, meet its endpoints?

No: MMPOWER-3, a 24-week trial of 218 people, did not meet its primary endpoints, with a 6-minute walk difference of -3.2 m (95% CI -18.7 to 12.3; p = 0.69) against placebo.6

What side effects of SS-31 are reported?

The label lists injection site reactions as occurring more commonly on elamipretide than on placebo and also reports hypersensitivity reactions and increased eosinophil counts.4

Is SS-31 banned by WADA?

The WADA 2026 Prohibited List text does not name SS-31 or elamipretide, and its section S0 covers substances with "no current approval by any governmental regulatory health authority for human therapeutic use".16

15

References

  1. Thompson WR, Hornby B, Manuel R, et al. A phase 2/3 randomized clinical trial followed by an open-label extension to evaluate the effectiveness of elamipretide in Barth syndrome, a genetic disorder of mitochondrial cardiolipin metabolism. Genet Med 2021. PMC7935714
  2. Shirley M. Elamipretide: First Approval. Drugs 2026. PMID 41335372
  3. US Food and Drug Administration, Center for Drug Evaluation and Research. Integrated review, NDA 215244, Forzinity (elamipretide): NDA resubmission review (completed 19 September 2025) and first-cycle review. 2025. FDA integrated review
  4. Stealth BioTherapeutics Inc. FORZINITY (elamipretide hydrochloride) injection, US prescribing information (DailyMed set ID 146bf34c-76f2-48db-ac07-fb29cce2cd75, version 11, effective 6 November 2026). DailyMed label
  5. US Food and Drug Administration. Accelerated approval letter, NDA 215244, Forzinity (elamipretide) injection, 19 September 2025. FDA approval letter
  6. Karaa A, Bertini E, Carelli V, et al. Efficacy and Safety of Elamipretide in Individuals With Primary Mitochondrial Myopathy: The MMPOWER-3 Randomized Clinical Trial. Neurology 2023. PMC10382259
  7. Butler J, Khan MS, Anker SD, et al. Effects of Elamipretide on Left Ventricular Function in Patients With Heart Failure With Reduced Ejection Fraction: The PROGRESS-HF Phase 2 Trial. J Card Fail 2020. PMID 32068002
  8. Ehlers JP, Hu A, Boyer D, et al. ReCLAIM-2: A Randomized Phase II Clinical Trial Evaluating Elamipretide in Age-related Macular Degeneration, Geographic Atrophy Growth, Visual Function, and Ellipsoid Zone Preservation. Ophthalmol Sci 2025. PMC11599447
  9. Sabbah HN, Alder NN, Sparagna GC, et al. Contemporary insights into elamipretide's mitochondrial mechanism of action and therapeutic effects. Biomed Pharmacother 2025. PMID 40294492
  10. Thompson WR, Manuel R, Abbruscato A, et al. Long-term efficacy and safety of elamipretide in patients with Barth syndrome: 168-week open-label extension results of TAZPOWER. Genet Med 2024. PMID 38602181
  11. Karaa A, Haas R, Goldstein A, et al. Randomized dose-escalation trial of elamipretide in adults with primary mitochondrial myopathy. Neurology 2018. PMC5890606
  12. ClinicalTrials.gov. NCT02788747: Effect of Elamipretide on Left Ventricular Function in Subjects With Stable Heart Failure With Reduced Ejection Fraction. Registry record, last updated 2020-05-14. NCT02788747
  13. Hornby B, Thompson WR, Almuqbil M, et al. Natural history comparison study to assess the efficacy of elamipretide in patients with Barth syndrome. Orphanet J Rare Dis 2022. PMC9438322
  14. ClinicalTrials.gov. NCT07531251: Clinical Trial in Patients With Barth Syndrome- 4TAZPower. Registry record, last updated 2026-11-09. NCT07531251
  15. ClinicalTrials.gov. NCT03323749: A Trial to Evaluate Safety and Efficacy of Elamipretide Primary Mitochondrial Myopathy Followed by Open Label Extension. Registry record, last updated 2022-01-24. NCT03323749
  16. World Anti-Doping Agency. World Anti-Doping Code International Standard Prohibited List 2026. WADA Prohibited List 2026
  17. ClinicalTrials.gov. NCT06373731: ReNEW:Phase 3 Study of Efficacy, Safety & Pharmacokinetics of Subcutaneous Injections of Elamipretide in Subjects With Dry Age-Related Macular Degeneration. Registry record, last updated 2026-09-17. NCT06373731
  18. ClinicalTrials.gov. NCT05162768: Study to Evaluate Efficacy and Safety of Elamipretide in Subjects With Primary Mitochondrial Disease From Nuclear DNA Mutations (nPMD). Registry record, last updated 2025-10-24. NCT05162768
  19. Gibson CM, Giugliano RP, Kloner RA, et al. EMBRACE STEMI study: a Phase 2a trial to evaluate the safety, tolerability, and efficacy of intravenous MTP-131 on reperfusion injury in patients undergoing primary percutaneous coronary intervention. Eur Heart J 2016. PMID 26586786
  20. Daubert MA, Yow E, Dunn G, et al. Novel Mitochondria-Targeting Peptide in Heart Failure Treatment: A Randomized, Placebo-Controlled Trial of Elamipretide. Circ Heart Fail 2017. PMID 29217757
  21. Karanjia R, Sadun AA. Elamipretide Topical Ophthalmic Solution for the Treatment of Subjects with Leber Hereditary Optic Neuropathy: A Randomized Trial. Ophthalmology 2024. PMID 37923251